Sanofi (SNYNF) Total Non-Current Liabilities (2009 - 2025)
Sanofi (SNYNF) posted Total Non-Current Liabilities of $31.1 billion for Q4 2025, up 7.37% sequentially from $29.0 billion in Q2 2025, and up 13.04% YoY from $27.5 billion in Q4 2024.
Sanofi (SNYNF) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 17 years of Total Non-Current Liabilities data on file, last reported at $31.1 billion in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 13.04% year-over-year to $31.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.1 billion (up 13.04% YoY) and the FY2025 annual result came in at $31.1 billion, up 13.04% from the prior year.
- Total Non-Current Liabilities improved to $31.1 billion in Q4 2025 per SNYNF's latest filing, from $29.0 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $35.9 billion in Q2 2021, with the low at $27.5 billion in Q4 2024.
- Average Total Non-Current Liabilities over 5 years is $30.5 billion, with a median of $30.0 billion recorded in 2023.
- Year-over-year, Total Non-Current Liabilities decreased 17.73% in 2022 and advanced 13.04% in 2025.
- Sanofi's Total Non-Current Liabilities stood at $34.2 billion in 2021, then declined by 17.73% to $28.2 billion in 2022, then rose by 6.64% to $30.0 billion in 2023, then slipped by 8.25% to $27.5 billion in 2024, then advanced by 13.04% to $31.1 billion in 2025.
- Business Quant data shows SNYNF's Total Non-Current Liabilities at $31.1 billion in Q4 2025, $29.0 billion in Q2 2025, and $27.5 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.14 Bn |
| Jun 30, 2025 | 29.00 Bn |
| Dec 31, 2024 | 27.55 Bn |
| Jun 30, 2024 | 28.79 Bn |
| Dec 31, 2023 | 30.02 Bn |
| Jun 30, 2023 | 30.06 Bn |
| Dec 31, 2022 | 28.15 Bn |
| Jun 30, 2022 | 30.35 Bn |
| Dec 31, 2021 | 34.22 Bn |
| Jun 30, 2021 | 35.90 Bn |
| Dec 31, 2020 | 38.01 Bn |
| Jun 30, 2020 | 36.93 Bn |
| Dec 31, 2019 | 272.41 Mn |
| Jun 30, 2019 | 39.13 Bn |
| Dec 31, 2018 | 39.95 Bn |
| Sep 30, 2018 | 426.87 Mn |
| Jun 30, 2018 | 134.56 Bn |
| Mar 31, 2018 | 42.47 Bn |
| Dec 31, 2017 | 30.74 Bn |
| Jun 30, 2017 | 29.70 Bn |